FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367693802> ?p ?o ?g. }

• W4367693802 endingPage "100646" @default.
• W4367693802 startingPage "100646" @default.
• W4367693802 abstract "Rationale & ObjectiveThe efficacy and safety profile of apixaban remains uncertain in patients receiving peritoneal dialysis (PD) despite increasing use in this population. Accordingly, we assessed the pharmacokinetics of apixaban among patients receiving PD.Study DesignA pharmacokinetics study in a single center. Patients recruited received 1 week of apixaban at 2.5 mg twice a day to reach steady state. Serial blood samples were then taken before and after the last dose for pharmacokinetics analysis of apixaban.Setting & ParticipantsTen stable PD patients with atrial fibrillation in an outpatient setting.Analytical Approach/OutcomesPharmacokinetic parameters including the area under the concentration-time curve from time 0 to 12 hours after the last dose of apixaban (AUC0-12), peak concentration, trough level, time to peak apixaban concentration, half-life, and drug clearance were analyzed.ResultsThere was a wide variation in the range of apixaban concentration across the 10 patients. The AUC0-12 for the PD group was significantly higher than those reported previously for hemodialysis patients or healthy individuals. Three patients had a supratherapeutic peak concentration whereas 2 patients had a supratherapeutic trough level as compared with the pharmacokinetic parameter in healthy individuals taking equivalent therapeutic dosage.LimitationsSmall sample size with short study duration limits the ability to ascertain the true bleeding risk and to detect any clinical outcomes. Results may be limited to Asian populations only.ConclusionsA proportion of PD patients had supratherapeutic levels even when the reduced dosage 2.5 mg twice a day was used. Given the large interindividual variation in the drug level, therapeutic drug monitoring should be done if available. Otherwise, one should start the drug at reduced doses with caution and with more frequent clinical monitoring for any signs of bleeding. The efficacy and safety profile of apixaban remains uncertain in patients receiving peritoneal dialysis (PD) despite increasing use in this population. Accordingly, we assessed the pharmacokinetics of apixaban among patients receiving PD. A pharmacokinetics study in a single center. Patients recruited received 1 week of apixaban at 2.5 mg twice a day to reach steady state. Serial blood samples were then taken before and after the last dose for pharmacokinetics analysis of apixaban. Ten stable PD patients with atrial fibrillation in an outpatient setting. Pharmacokinetic parameters including the area under the concentration-time curve from time 0 to 12 hours after the last dose of apixaban (AUC0-12), peak concentration, trough level, time to peak apixaban concentration, half-life, and drug clearance were analyzed. There was a wide variation in the range of apixaban concentration across the 10 patients. The AUC0-12 for the PD group was significantly higher than those reported previously for hemodialysis patients or healthy individuals. Three patients had a supratherapeutic peak concentration whereas 2 patients had a supratherapeutic trough level as compared with the pharmacokinetic parameter in healthy individuals taking equivalent therapeutic dosage. Small sample size with short study duration limits the ability to ascertain the true bleeding risk and to detect any clinical outcomes. Results may be limited to Asian populations only. A proportion of PD patients had supratherapeutic levels even when the reduced dosage 2.5 mg twice a day was used. Given the large interindividual variation in the drug level, therapeutic drug monitoring should be done if available. Otherwise, one should start the drug at reduced doses with caution and with more frequent clinical monitoring for any signs of bleeding." @default.
• W4367693802 created "2023-05-03" @default.
• W4367693802 creator A5007190507 @default.
• W4367693802 creator A5010256187 @default.
• W4367693802 creator A5019207502 @default.
• W4367693802 creator A5020038563 @default.
• W4367693802 creator A5057029922 @default.
• W4367693802 creator A5077717261 @default.
• W4367693802 creator A5082050067 @default.
• W4367693802 date "2023-08-01" @default.
• W4367693802 modified "2023-09-30" @default.
• W4367693802 title "Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients" @default.
• W4367693802 cites W1507763452 @default.
• W4367693802 cites W1568662837 @default.
• W4367693802 cites W1913544684 @default.
• W4367693802 cites W1993406555 @default.
• W4367693802 cites W2008203103 @default.
• W4367693802 cites W2014822095 @default.
• W4367693802 cites W2031100777 @default.
• W4367693802 cites W2037053691 @default.
• W4367693802 cites W2055619480 @default.
• W4367693802 cites W2062346376 @default.
• W4367693802 cites W2063909696 @default.
• W4367693802 cites W2073510057 @default.
• W4367693802 cites W2092332131 @default.
• W4367693802 cites W2116532362 @default.
• W4367693802 cites W2123217665 @default.
• W4367693802 cites W2142970733 @default.
• W4367693802 cites W2439026761 @default.
• W4367693802 cites W2463716288 @default.
• W4367693802 cites W2571124477 @default.
• W4367693802 cites W2579957291 @default.
• W4367693802 cites W2588575739 @default.
• W4367693802 cites W2596305759 @default.
• W4367693802 cites W2790801037 @default.
• W4367693802 cites W2791056163 @default.
• W4367693802 cites W2897274926 @default.
• W4367693802 cites W2897495391 @default.
• W4367693802 cites W2945246723 @default.
• W4367693802 cites W2946652117 @default.
• W4367693802 cites W2997217735 @default.
• W4367693802 cites W3006253728 @default.
• W4367693802 cites W3007155477 @default.
• W4367693802 cites W3122758050 @default.
• W4367693802 cites W3135760900 @default.
• W4367693802 cites W3168272973 @default.
• W4367693802 cites W4206007300 @default.
• W4367693802 doi "https://doi.org/10.1016/j.xkme.2023.100646" @default.
• W4367693802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37533565" @default.
• W4367693802 hasPublicationYear "2023" @default.
• W4367693802 type Work @default.
• W4367693802 citedByCount "1" @default.
• W4367693802 countsByYear W43676938022023 @default.
• W4367693802 crossrefType "journal-article" @default.
• W4367693802 hasAuthorship W4367693802A5007190507 @default.
• W4367693802 hasAuthorship W4367693802A5010256187 @default.
• W4367693802 hasAuthorship W4367693802A5019207502 @default.
• W4367693802 hasAuthorship W4367693802A5020038563 @default.
• W4367693802 hasAuthorship W4367693802A5057029922 @default.
• W4367693802 hasAuthorship W4367693802A5077717261 @default.
• W4367693802 hasAuthorship W4367693802A5082050067 @default.
• W4367693802 hasBestOaLocation W43676938021 @default.
• W4367693802 hasConcept C112705442 @default.
• W4367693802 hasConcept C126322002 @default.
• W4367693802 hasConcept C19831878 @default.
• W4367693802 hasConcept C2776301958 @default.
• W4367693802 hasConcept C2778063415 @default.
• W4367693802 hasConcept C2778661090 @default.
• W4367693802 hasConcept C2779056158 @default.
• W4367693802 hasConcept C2779161974 @default.
• W4367693802 hasConcept C2779978075 @default.
• W4367693802 hasConcept C2780035454 @default.
• W4367693802 hasConcept C2780272996 @default.
• W4367693802 hasConcept C2780638905 @default.
• W4367693802 hasConcept C2908647359 @default.
• W4367693802 hasConcept C2910800852 @default.
• W4367693802 hasConcept C71924100 @default.
• W4367693802 hasConcept C98274493 @default.
• W4367693802 hasConcept C99454951 @default.
• W4367693802 hasConceptScore W4367693802C112705442 @default.
• W4367693802 hasConceptScore W4367693802C126322002 @default.
• W4367693802 hasConceptScore W4367693802C19831878 @default.
• W4367693802 hasConceptScore W4367693802C2776301958 @default.
• W4367693802 hasConceptScore W4367693802C2778063415 @default.
• W4367693802 hasConceptScore W4367693802C2778661090 @default.
• W4367693802 hasConceptScore W4367693802C2779056158 @default.
• W4367693802 hasConceptScore W4367693802C2779161974 @default.
• W4367693802 hasConceptScore W4367693802C2779978075 @default.
• W4367693802 hasConceptScore W4367693802C2780035454 @default.
• W4367693802 hasConceptScore W4367693802C2780272996 @default.
• W4367693802 hasConceptScore W4367693802C2780638905 @default.
• W4367693802 hasConceptScore W4367693802C2908647359 @default.
• W4367693802 hasConceptScore W4367693802C2910800852 @default.
• W4367693802 hasConceptScore W4367693802C71924100 @default.
• W4367693802 hasConceptScore W4367693802C98274493 @default.
• W4367693802 hasConceptScore W4367693802C99454951 @default.
• W4367693802 hasIssue "8" @default.
• W4367693802 hasLocation W43676938021 @default.

• next